evenfolio

Healthcare · NSE: AKUMS

Akums Drugs and Pharmaceuticals

Q2 FY27 earnings and concall highlights

Price as of 16 Nov 2026
722.20−2.54%

Q2 FY27 earnings call · Guided by management

Call held 3 Nov 2026 · Read the filing on NSEFiling

10–15​%Baddi share of CDMO business · CDMO · 3 years from nowMaheshwari · Q&A · p. 10
3–4​quartersTime to API EBITDA breakeven · API · next 3, 4 quartersMaheshwari · p. 8
8–10​%Revenue growth · Domestic branded formulationsMaheshwari · Q&A · p. 10
₹210​CrH1 investment · H1 FY27Sood · p. 9
M.Cap
₹11,367Cr
P/E
31.2×
1Y return
+70.21%
From 52W high
−13.9%

Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.

Share price

Results Q2 FY27, as filed · consolidated · ₹ Cr

Q2 FY27Q2 FY26YoYQ1 FY27QoQ
Revenue1,3421,018+31.9%1,167+15.1%
EBITDA19594+106.1%175+11.5%
EBITDA margin14.5%9.3%+523 bps15.0%-46 bps
PBTProfit before tax15566+135.6%139+11.1%
Net profit11341+176.7%100+12.8%
EPS (₹)7.372.66+177.1%6.53+12.9%

From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures.

Guidance

Revenue growth · Domestic branded formulations · long term8-10%Domestic branded business aims to keep 8% to 10% growth
CapexRs 300 CrReason given: Baddi start-up and plant acquisition

Domestic branded formulations: Domestic branded formulations expected to grow on par with IPM by FY28

Sandeep Jain · Managing Director · p. 4
“We expect the segment to deliver growth on par with IPM by FY28 as the current initiatives start bearing fruits.”

API: API full-year losses expected to be lower than last year

Sumeet Sood · Chief Financial Officer · p. 5
“We continue to focus on higher gross margin products and expect the full year losses to be lower than last year.”

More figures from the call

beauty and personal care · Guidance
3​×Peak revenue as multiple of purchase price · peak
“So Oriflame, we bought it at around INR56 crores. This is again, as I was mentioning to an earlier question, we expect that peak should deliver a 3x revenue for us.”
Sahil Maheshwari · Headp. 10
CDMO · Guidance
3–3.5​%R&D spend as share of CDMO revenue
“As we move into the regulated markets, we expect this R&D expense also to move up. But broadly 3%-odd, 3%, 3.5% is something for the sake from the CDMO revenue that we expect to reinvest into quality pipeline assets.”
Sahil Maheshwari · Headp. 13
Company · Capacity
50​%Utilization
“We today operate at healthy utilization levels of above 50%.”
Sandeep Jain · Managing Directorp. 3
CDMO · Capacity
6​billion unitsAnnual capacity, oral solids Phase 1 · Q1 FY28
“The plant will have oral solids in Phase 1 with an annual capacity of over 6 billion units, which will fully operationalize by Q1 FY28.”
Sandeep Jain · Managing Directorp. 4
CDMO · Capacity
12​billion tabletsBaddi facility tablet capacity
“Then we'll have another phase of it, which will contribute another 6 billion-odd tablets from it. So, we'll have roughly 12 billion tablets from this facility.”
Sahil Maheshwari · Headp. 7
CDMO · Capacity
50–51​billion unitsAnnual capacity
“So, we largely have 50 billion, 51 billion annual capacity.”
Sahil Maheshwari · Headp. 7

In short

  1. 01Q2 FY27 consolidated revenue was INR 1,342 crore, up 31.9% year on year; PAT was INR 115 crore.
  2. 02CDMO revenue was INR 1,115 crore, up 38.6% year on year, with volume growth above 20%.
  3. 03New Baddi plant Phase 1 adds over 6 billion oral solid units, fully operational by Q1 FY28.
  4. 04Baddi facility expected to deliver at least 10% to 15% of the CDMO business in 3 years.
  5. 05Zambia supplies due Q4 FY27 with revenue booked in Q1 FY28; the $25 million business is intact.
  6. 06European CDMO supplies to start in FY28; dossier approval may take 1 or 2 quarters.
  7. 07API segment aims to break even over the next 3 to 4 quarters.
  8. 08Management does not give specific revenue guidance for the company or its verticals.

Capex

CDMO: Oral solids plants usually give 3x revenue turn on gross block

Sahil Maheshwari · Head · Q&A · p. 7
“usually what we do observe in oral solids, we usually have 3x the turn in our gross block for the revenue.”

Around INR 43 crore invested in the Baddi plant

Sumeet Sood · Chief Financial Officer · p. 9
“investment in the Baddi plant of around INR43-odd crores.”

Maintenance capex of 5% on INR 2,400 crore gross block, about INR 100 crore

Sumeet Sood · Chief Financial Officer · p. 9
“mentioning that on a gross block of INR2,400 crores, if we are spending 5% on the maintenance capex, INR100 crores gets into the plants.”

Zambia JV: Zambia plant expected to become operational in 2029

Sandeep Jain · Managing Director · p. 4
“The plant is expected to become operational in 2029, expanding our manufacturing presence outside India.”

Capacity

CDMO: Baddi Phase 1 to be operational in the next 3 to 4 months

Sahil Maheshwari · Head · Q&A · p. 7
“So, as I said, this is a large facility, the Phase 1 of which will be operational in the next 3, 4 months.”

CDMO: Baddi facility to be brought into operation in 3 phases

Sahil Maheshwari · Head · p. 10
“So Baddi, as I said, we'll gradually in 3 phases operationalize this facility.”

CDMO: Other dosage forms also planned at the new Baddi facility

Sahil Maheshwari · Head · p. 7
“Apart from this, we are also planning some other dosage forms within this facility itself.”

Order book

Zambia JV: Zambia business of $25 million intact, margins slightly better than CDMO

Sahil Maheshwari · Head · Q&A · p. 6
“So, the business is, as you rightly said, $25 million fully intact with a margin profile which are slightly better than our CDMO margins.”

Zambia JV: Zambia purchase orders received after the presidential election

Sahil Maheshwari · Head · p. 6
“Soon after it, we went into discussing the purchase order and we have now received the purchase orders.”

Segments

Europe: Europe: 2 products approved, 8 filed, over 30 in R&D to commercialise over 3-4 years

Sandeep Jain · Managing Director · p. 4
“We have 2 products approved in Europe, 8 filed and over 30 in R&D, which we expect to commercialize over next 3-4 years.”

European CDMO: European CDMO project on plan, with supplies starting in FY28

Sandeep Jain · Managing Director · p. 4
“Our European CDMO project is progressing as per our stated plans with supplies commencing in FY28.”

Zambia JV: Zambia JV supplies scheduled for Q4 FY27, revenue expected in Q1 FY28

Sandeep Jain · Managing Director · p. 4
“Our JV with the Zambia government is also progressing smoothly with commercial supplies from the Indian plant scheduled during Q4 FY27 and considering the prolonged shipping time to Zambia, we expect to book revenues during Q1 FY28.”

International branded formulations: International branded business expected to keep its growth pace this year

Sandeep Jain · Managing Director · p. 4
“It is expected to maintain this momentum going forward in the year and will be key engine to drive Akums' growth.”

Trade generics: Trade generics EBITDA positive for third straight quarter

Sandeep Jain · Managing Director · p. 4
“The trade generics segment remained EBITDA positive during the quarter with the third straight quarter of achieving profitability.”

Demand

CDMO: CDMO volume growth of more than 20% on September MAT basis

Sandeep Jain · Managing Director · p. 3
“Led by strong order book and improved utilization of newer facilities, the CDMO business achieved a volume growth of more than 20% on September net MAT basis”

CDMO: Input material prices volatile; CDMO demand outlook described as strong

Sandeep Jain · Managing Director · p. 3
“While the availability and the prices of input materials remain volatile, the demand outlook for CDMO remains strong.”

CDMO: CDMO has about 60 days of order visibility; volume growth described as healthy

Sahil Maheshwari · Head · p. 14
“On the volumes, as of now as I said, we have seen multiple quarters where the volume growth was significant and we have a 60-odd day of order cycle visibility.”

CDMO: Management says coming CDMO quarters look healthy

Sahil Maheshwari · Head · p. 7
“The coming quarters also look healthy and encouraging.”

CDMO: CDMO mix has no tilt to any therapy or dosage form

Sahil Maheshwari · Head · Q&A · p. 11
“So, to answer your question, we don't have any tilt towards any therapy, skewed towards any dosage forms.”

Margins and costs

EBITDA margin 14.5% vs 9.3% in Q2 FY26 and 15% in Q1 FY27

Sumeet Sood · Chief Financial Officer · p. 5
“Margins were healthy at 14.5% as against 9.3% in Q2 FY26 and 15% in Q1 FY27.”

API prices up 2% to 3% quarter on quarter and 5% to 7% year on year

Sahil Maheshwari · Head · p. 13
“If you really look at it quarter-on-quarter, these have moved roughly 2% to 3%. While if we compare it to last quarter 2 FY26, these would have moved up by 5% to 7% as a basket.”

API prices expected to move slightly upward this quarter

Sahil Maheshwari · Head · p. 13
“We expect there should be some slight upward movements only in the API prices at least in this quarter and that's how to view the 2, 3 months.”

Domestic branded formulations: Akumentis keeps 74% to 75% gross margin

Sahil Maheshwari · Head · p. 14
“On the Akumentis, if you really look at on the gross margin level, this has continued maintaining a 74%, 75% gross margin business.”

Domestic branded formulations: Domestic branded EBITDA drag from MR count rising from 1,400 to 1,600

Sahil Maheshwari · Head · Q&A · p. 14
“So most of our EBITDA drag was due to an investment into the manpower. So we broadly moved up from a 1,400 MR count to a 1,600 MR count on top of which, there is a 450 line manager across both second and third line managers.”

Debt and working capital

Cash and cash equivalents at INR 1,680 crore

Sumeet Sood · Chief Financial Officer · p. 5
“Our balance sheet continues to remain healthy and cash and cash equivalent as has been constantly increasing stands at INR1,680 crores.”

H1 free cash flow INR 45.5 crore after business acquisition

Sumeet Sood · Chief Financial Officer · p. 5
“The company had a free cash flow for H1 of INR45.5 crores after account for business acquisition”

European CDMO: Remaining 80 million of European advance to be set off over contract period

Sumeet Sood · Chief Financial Officer · Q&A · p. 9
“will probably have the advance, which is the 80 million which is left of the first 20 million, that will probably get set off and the remaining money will start coming in with the supplies.”

Fund raising

Baddi to be funded by loans if cheaper than investment returns, else own investments

Sumeet Sood · Chief Financial Officer · p. 7
“If the loans are available at lower the cost of our investment, we'll take loans. Otherwise, we'll liquidate our investment.”

Acquisitions and new business

beauty and personal care: Two plants acquired from Oriflame integrated during the quarter

Sandeep Jain · Managing Director · p. 3
“During the quarter, we successfully integrated the 2 manufacturing plants acquired from Oriflame.”

API: API: 2 CEPs approved, 2 more in pipeline

Sahil Maheshwari · Head · p. 7
“We have 2 CEPs which are approved, 2 more CEPs are in pipeline.”

Oriflame deal was about INR 56 crore

Sumeet Sood · Chief Financial Officer · p. 9
“Oriflame deal, which was in the public domain, was of around INR56 crores.”

beauty and personal care: Oriflame business to contribute meaningfully in a couple of years

Sahil Maheshwari · Head · p. 10
“So, this year largely is a period where we will build upon customers and revenue and gradually this business in couple of years should start meaningfully contributing.”

CDMO: About 2 to 3 DCGI approvals a month, near 30 a year

Sahil Maheshwari · Head · p. 12
“So we usually get almost 2 to 3 DCGIs every month, which takes our tally to almost 30-odd DCGIs annually.”

Risks

No financial liability seen from NPPA notice; disclosure made under LODR

Sumeet Sood · Chief Financial Officer · p. 9
“So, because the way the notice was issued both to us and them, as per the LODR, we are supposed to make a disclosure. So, we do not have any financial liability.”

No provision made for the NPPA notice

Sumeet Sood · Chief Financial Officer · Q&A · p. 9
“No provisioning. No, nothing at all, sir. Nothing at all.”

Other

European CDMO: European dossier filed; approval may take 1 or 2 quarters

Sahil Maheshwari · Head · p. 6
“The dossier has been filed. While it is up to the regulator, we believe that it could take 1 or 2 quarters by the time we receive the approval of the dossier.”

Company moved to S/4HANA during the quarter

Sandeep Jain · Managing Director · p. 4
“We also successfully transitioned to S/4HANA this quarter.”

Company received an EcoVadis Bronze medal

Sandeep Jain · Managing Director · p. 4
“We are proud to announce that our company has an EcoVadis Bronze medal.”

Q2 FY27 consolidated revenue INR 1,342 crore, up 31.9% year on year

Sumeet Sood · Chief Financial Officer · p. 5
“Revenue on a consolidated basis stood at INR1,342 crores; an increase of 31.9% year-on-year”

Q2 FY27 profit after tax INR 115 crore, up 168.3% year on year

Sumeet Sood · Chief Financial Officer · p. 5
“Profit after tax stood at INR115 crores; an increase of 168.3% year-on-year, Q2 FY26, it was INR43 crores”

Sources

Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

Search

Search funds, ETFs, stocks, pages and tools